StreetInsider.com News Articles

Form 10-K Autonomix Medical, Inc. For: Mar 31

Wed, 27 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260527/26558430.html

Form 10-K Autonomix Medical, Inc. For: Mar 31

Wed, 27 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260527/26558430.html

Autonomix Medical receives US patent for transvascular monitoring system

Tue, 19 May 2026 08:30:32 -0400

Autonomix Medical Inc. (NASDAQ: AMIX) announced the U.S. Patent and Trademark Office issued Patent No. 12,544,131 for systems that monitor and treat tissues within and through lumen walls. The patent covers catheter-based transvascular tools designed to operate from within bodily lumens, with deployable probes that penetrate vessel walls to access external tissues and nerves.

The patent includes claims for multi-site electrophysiological sensing at target, secondary, and reference sites to improve signal quality. It encompasses methods for assessing procedural completion based on electrophysiological signal processing, including detection of changes in neural activity patterns to evaluate treatment effects.

"Current catheter-based neuromodulation procedures often lack

Autonomix Medical receives US patent for transvascular monitoring system

Tue, 19 May 2026 08:30:32 -0400

"Current catheter-based neuromodulation procedures often lack

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

Tue, 19 May 2026 08:30:00 -0400

Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall

Patent strengthens intellectual property foundation for next-generation neuromodulation technologies

THE WOODLANDS, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,544,131 (the “131 patent”), titled “Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within And/Or Through a Lumen Wall.”

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

Tue, 19 May 2026 08:30:00 -0400

Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall

Patent strengthens intellectual property foundation for next-generation neuromodulation technologies

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

Tue, 19 May 2026 08:30:00 -0400

Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall

Patent strengthens intellectual property foundation for next-generation neuromodulation technologies

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

Tue, 19 May 2026 08:30:00 -0400

Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall

Patent strengthens intellectual property foundation for next-generation neuromodulation technologies

Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation

Mon, 18 May 2026 08:45:00 -0400

THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two abstracts highlighting the Company’s innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, the world-leading course in interventional cardiovascular medicine, taking place May 19–22, 2026 in Paris, France.

The accepted abstracts titled, “Pain mitigation in pancreatic cancer: An analysis of denervation via transvascular RF ablation” and “Illuminating the nervous system with transvascular precision-guided technology”, further recognize

Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation

Mon, 18 May 2026 08:45:00 -0400

Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation

Mon, 18 May 2026 08:45:00 -0400

Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation

Mon, 18 May 2026 08:45:00 -0400

Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation

Wed, 29 Apr 2026 08:45:00 -0400

THE WOODLANDS, TX, April 29, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its long-term data titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation” has been accepted for presentation at Digestive Disease Week 2026 (DDW 2026), being held May 2–5, 2026, in Chicago, IL and virtually.

Pancreatic adenocarcinoma is frequently associated with severe, debilitating pain that significantly impacts patient quality of life. The data to

Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation

Wed, 29 Apr 2026 08:45:00 -0400

Pancreatic adenocarcinoma is frequently associated with severe, debilitating pain that significantly impacts patient quality of life. The data to

Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026

Wed, 22 Apr 2026 08:42:00 -0400

THE WOODLANDS, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that new long-term clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the European Conference on Interventional Oncology (ECIO) 2026 being held April 26 – 30, 2026 in Basel CH.

The presentation, titled “Pain mitigation in pancreatic adenocarcinoma: a long-term analysis of denervation via transvascular RF energy-based ablation”

Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026

Wed, 22 Apr 2026 08:42:00 -0400

The presentation, titled “Pain mitigation in pancreatic adenocarcinoma: a long-term analysis of denervation via transvascular RF energy-based ablation”

Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026

Wed, 22 Apr 2026 08:42:00 -0400

The presentation, titled “Pain mitigation in pancreatic adenocarcinoma: a long-term analysis of denervation via transvascular RF energy-based ablation”

Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026

Wed, 22 Apr 2026 08:42:00 -0400

The presentation, titled “Pain mitigation in pancreatic adenocarcinoma: a long-term analysis of denervation via transvascular RF energy-based ablation”

Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026

Wed, 08 Apr 2026 08:40:00 -0400

THE WOODLANDS, TX, April 08, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that its abstract titled, “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation,” has been selected as a Featured Abstract for podium presentation at the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Canada.

The abstract is among a select group recognized for its

Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026

Wed, 08 Apr 2026 08:40:00 -0400

The abstract is among a select group recognized for its

Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026

Wed, 08 Apr 2026 08:40:00 -0400

The abstract is among a select group recognized for its

Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026

Wed, 08 Apr 2026 08:40:00 -0400

The abstract is among a select group recognized for its

Form S-8 Autonomix Medical, Inc.

Thu, 02 Apr 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260402/26268232.html

Form S-8 Autonomix Medical, Inc.

Thu, 02 Apr 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260402/26268232.html

Autonomix Medical to Present at LSI USA ’26

Wed, 11 Mar 2026 08:40:00 -0400

THE WOODLANDS, TX, March 11, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Brad Hauser, President and Chief Executive Officer of Autonomix will present at LSI USA ’26 on Tuesday, March 17, 2026 at 9:15 AM PT.

In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

The